TrialOrphanet journal of rare diseases2016

Oral epigallocatechin-3-gallate for treatment of dystrophic epidermolysis bullosa: a multicentre, randomized, crossover, double-blind, placebo-controlled clinical trial.

Christine Chiaverini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.